Thiazovivin, Free Base, >99%
Catalog Number: T-9753
Synonyms : [Tzv]
Synonyms : [Tzv]
- View the SDS for this product
- Triazovivin is a Rock inhibitor. It inhibited the apoptosis of human embryonic stem cells (hESCs) upon dissociation. Kajabadi E., et al. "Computational predictions of intracellular thiazovivin interactions as one of the best hESCs apoptosis inhibitors." Res. Pharm. Sci. 7: S685 (2012).
- Triazovivin dramatically enhanced the survival of hESCs upon trypsinization. Lin T., et al. "A chemical platform for improved induction of human iPSCs." Nat. Methods 6: 805-808 (2009).
- Thiazovivin improved extracellular matrix (ECM) adhesion-mediated integrin signaling and protected hESCs in the absence of ECM, possibly by regulating E-cadherin-mediated cell-cell interaction. Thiazovivin improved survival of single hESCs more than 30-fold on matrigel-coated plates after enzymatic dissociation. Xu Y., et al. "Revealing a core signaling regulatory mechanism for pluripotent stem cell survival and self-renewal by small molecules." Proc. Natl. Acad. Sci. USA 107: 8129-8134 (2010).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.